Patients harboring activating mutations in GUCY2C present with varying degrees of inflammation in the gut (such as esophagitis, irritable bowel syndrome [IBS], CD, and ulcerative colitis [UC]; Fiskerstrand et al., 2012; Müller et al., 2016). This evidence concerns the gene GUCY2C and irritable bowel syndrome.